Company also reports encouraging partial results from Phase IIa study of continuous, subcutaneously delivered high-dose liquid levodopa/carbidopa (ND0612H) therapy for advanced patients
What does L/C stand for?
L/C stands for Levodopa/Carbidopa
This definition appears very rarely and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of L/C
We have 121 other meanings of L/C in our Acronym Attic
- Live Purified Vaccinia Virus
- Long-Term Potentiation
- Liver/Aortic Ratio
- Lesion to Background
- Lung/Blood Ratio
- Lecithin-to-Bile-Salt (molar ratio)
- Landed Cost
- Laydays/Canceling (shipping)
- Letter of Credit
Samples in periodicals archive:
Levodopa/carbidopa has been shown to improve sleep at lower doses, however at higher doses may disrupt sleep with nightmares, hallucinations, vocalizations, and excessive daytime sleepiness.
It has been under FDA review as adjunctive therapy to levodopa/carbidopa for the treatment of idiopathic Parkinson's disease to improve motor function in patients who experience motor response complications.
Clinical and biochemical studies with controlled-release levodopa/carbidopa.
Title: Continuous Subcutaneous Administration of Levodopa/Carbidopa (ND0612) for the Treatment of Parkinson's Disease Presenter: Sheila Oren MD Session: Symptomatic Therapies Date and time: Wednesday, October 29[sup.
Based on the clinical efficacy and safety data obtained, the company submitted a NDA for Istradefylline(KW-6002) as adjunctive therapy to levodopa/carbidopa for the treatment of idiopathic Parkinson's disease to improve motor function in patients who experience motor response complications.
The drug was approved as Tasmar in January 1998 for adjunctive use in patients whose Parkinson's symptoms are not adequately controlled despite being on adequate doses of levodopa/carbidopa, according to the FDA.
NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.